LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-5.77%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$1.17B
AUM Growth
+$1.17B
(+14%)
Cap. Flow
+$299M
Cap. Flow
% of AUM
25.68%
Top 10 Holdings %
Top 10 Hldgs %
51.12%
Holding
71
New
18
Increased
15
Reduced
14
Closed
14
Top Buys
| 1 |
VERV
Verve Therapeutics
VERV
|
$45.7M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$38M |
| 3 |
LENZ
LENZ Therapeutics
LENZ
|
$32.9M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$29.3M |
| 5 |
Century Therapeutics
IPSC
|
$29M |
Top Sells
| 1 |
Dyne Therapeutics
DYN
|
$24.2M |
| 2 |
Repare Therapeutics
RPTX
|
$17.8M |
| 3 |
BioXcel Therapeutics
BTAI
|
$17.3M |
| 4 |
Kymera Therapeutics
KYMR
|
$10.1M |
| 5 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
$9.26M |
Sector Composition
| 1 | Healthcare | 99.71% |
| 2 | Financials | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $173M | 14.51% |
3,156,981
| – | – |
|
2
Olema Pharmaceuticals
OLMA
$375M
| $105M | 8.8% |
3,743,875
| – | – |
|
3
Design Therapeutics
DSGN
$315M
| $54.3M | 4.57% |
2,732,501
| – | – |
|
|
VERV
4
DELISTED
Verve Therapeutics
VERV
| $45.7M | 3.84% |
+758,265
| New | +$45.7M |
|
|
5
Dyne Therapeutics
DYN
$1.92B
| $43.2M | 3.63% |
2,054,392
-1,150,000
| -36% | -$24.2M |
|
|
DCPH
6
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $40.3M | 3.38% |
1,100,000
+1,038,000
| +1,674% | +$38M |
|
|
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $37M | 3.11% |
325,000
+125,000
| +63% | +$14.2M |
|
|
LENZ
8
LENZ Therapeutics
LENZ
$1.1B
| $32.9M | 2.77% |
+1,070,762
| New | +$32.9M |
|
9
Instil Bio
TIL
$182M
| $32.8M | 2.76% |
1,696,850
-150,000
| -8% | -$2.9M |
|
|
CMPS
10
Compass Pathways
CMPS
$424M
| $32.4M | 2.73% |
850,000
+600,000
| +240% | +$22.9M |
|
11
Nkarta
NKTX
$151M
| $31.8M | 2.67% |
1,002,382
-258,495
| -21% | -$8.19M |
|
|
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $31.2M | 2.62% |
400,000
+260,000
| +186% | +$20.3M |
|
|
KNTE
13
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $31M | 2.6% |
1,329,602
+395,000
| +42% | +$9.2M |
|
|
FMTX
14
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $30.2M | 2.54% |
1,215,000
-195,000
| -14% | -$4.85M |
|
|
15
Iovance Biotherapeutics
IOVA
$807M
| $29.3M | 2.46% |
+1,125,000
| New | +$29.3M |
|
|
16
Century Therapeutics
IPSC
$42.5M
| $29M | 2.44% |
+989,095
| New | +$29M |
|
17
Cytokinetics
CYTK
$4.23B
| $27.7M | 2.33% |
1,400,000
+700,000
| +100% | +$13.9M |
|
18
Edgewise Therapeutics
EWTX
$1.51B
| $26.3M | 2.21% |
1,231,812
+175,000
| +17% | +$3.73M |
|
19
Apellis Pharmaceuticals
APLS
$3.48B
| $22.1M | 1.86% |
+350,000
| New | +$22.1M |
|
|
BCYC
20
Bicycle Therapeutics
BCYC
$511M
| $21.7M | 1.82% |
715,000
-85,000
| -11% | -$2.58M |
|
|
CNTA
21
Centessa Pharmaceuticals
CNTA
$2.25B
| $20.9M | 1.75% |
+939,545
| New | +$20.9M |
|
22
Biomea Fusion
BMEA
$116M
| $18.1M | 1.52% |
+1,162,320
| New | +$18.1M |
|
|
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $15.8M | 1.33% |
2,500,000
+1,300,000
| +108% | +$8.2M |
|
24
GH Research
GHRS
$837M
| $15.7M | 1.32% |
+724,333
| New | +$15.7M |
|
25
Athira Pharma
ATHA
$15.3M
| $14.4M | 1.21% |
1,410,812
+400,000
| +40% | +$4.1M |
|